VYNE Therapeutics
VYNE
VYNE
52 hedge funds and large institutions have $161M invested in VYNE Therapeutics in 2018 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 5 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
52
Holders Change
+4
Holders Change %
+8.33%
% of All Funds
1.19%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
18
Reduced
5
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.8M |
2 |
First Manhattan
New York
|
+$9.03M |
3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.9M |
4 |
O
OrbiMed
New York
|
+$4.66M |
5 |
![]()
JPMorgan Chase & Co
New York
|
+$4.62M |
Top Sellers
1 |
PA
Perceptive Advisors
New York
|
-$10.1M |
2 |
![]()
Fidelity Investments
Boston,
Massachusetts
|
-$9.08M |
3 |
Millennium Management
New York
|
-$1.74M |
4 |
D.E. Shaw & Co
New York
|
-$231K |
5 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$200K |